Source: Annual Congress 2009 - Pulmonary circulation II
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Ichimori, S. Kogaki, H. Ishida, J. Narita, T. Uchikawa, S. Maekawa, S. Matsumoto, Y. Okada, K. Ozono (Suita, Japan). The adverse effect of estrogen on bone morphogenetic protein receptor (BMPR) signal pathway in pulmonary arterial endothelial cells (PAEC). Eur Respir J 2009; 34: Suppl. 53, 3920

Member's Comments

No comment yet.

Related content which might interest you: Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017 Year: 2017 Bone morphogenetic proteins (BMPs) inhibit hypoxia stimulated human pulmonary artery fibroblast (PAF) proliferation via inhibition of p38 MAP kinase and HIF-1α Source: Annual Congress 2004 - Pathophysiology of pulmonary hypertension Year: 2004 Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension Source: Eur Respir J 2009; 34: 1100-1110 Year: 2009 Sphingosine-1-phosphate receptor 1 controls endothelial cells permeability and function through the Bone morphogenetic 9/Endoglin signaling pathway. Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair Year: 2019 Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Dysregulated bone morphogenetic protein signaling in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Expression of angiogenic growth factors and stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis in idiopathic pulmonary fibrosis: a lung tissue study Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008 Effects of hypoxia on VEGF and VEGF-R expression by human alveolar epithelial (ATII) and human pulmonary microvascular endothelial (HMVEC-l) cells Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury Year: 2008 The microRNA cluster 17/92 regulates the expression of the bone morphogenetic protein receptor type II involved in the pathogenesis of pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Expression of bradykinin B2 receptor (B2R) and vascular endothelial growth factor (VEGF) in asthma and COPD Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007 ErbB receptor regulation by dexamethasone in mouse type II epithelial cells Source: Eur Respir J 2006; 28: 1117-1123 Year: 2006 Bone morphogenetic protein receptor-II as a regulator of pulmonary artery endothelial cell permeability: Relevance to the initiation and progression of heritable pulmonary arterial hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Effect of dexamethasone on TNFα-induced expression of vascular endothelial growth factor (VEGF) in human airway smooth muscle cells - role of histone-acetylation Source: Eur Respir J 2004; 24: Suppl. 48, 695s Year: 2004 Caveolin-1 regulation of thrombin signalling in endothelial cells Source: Annual Congress 2009 - Acute lung injury: biological mechanisms Year: 2009 Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Glucocorticoids promote TGF-β signalling in lung fibroblasts by upregulating ligand and receptor expression, and uncoupling negative-feedback inhibition Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Increased vascular endothelial growth factor (VEGF) secretion from activated T cells in COPD Source: Annual Congress 2007 - Cell-based tissue modulation: the good and the ugly? Year: 2007 Oral presentation: The bone morphogenetic protein antagonist Gremlin in pulmonary hypertension Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 IL18 induces p38 MAP kinase activation and adhesion capacities in BMPRII knocked down human lung microvascular endothelial cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018